Viridian Therapeutics, Inc. (NASDAQ:VRDN – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the eleven research firms that are currently covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $35.80.
VRDN has been the topic of several analyst reports. Royal Bank of Canada restated an “outperform” rating and set a $44.00 price objective on shares of Viridian Therapeutics in a report on Thursday, September 19th. Wedbush reaffirmed an “outperform” rating and issued a $42.00 price target on shares of Viridian Therapeutics in a report on Monday, July 29th. Oppenheimer reissued an “outperform” rating and set a $28.00 price objective (down from $31.00) on shares of Viridian Therapeutics in a report on Monday, August 12th. BTIG Research upped their target price on shares of Viridian Therapeutics from $56.00 to $61.00 and gave the company a “buy” rating in a research note on Thursday, September 26th. Finally, The Goldman Sachs Group lifted their price target on Viridian Therapeutics from $25.00 to $31.00 and gave the stock a “buy” rating in a research note on Thursday, September 12th.
Read Our Latest Report on VRDN
Insider Activity at Viridian Therapeutics
Institutional Investors Weigh In On Viridian Therapeutics
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Ameritas Investment Partners Inc. raised its position in shares of Viridian Therapeutics by 19.2% during the 1st quarter. Ameritas Investment Partners Inc. now owns 4,961 shares of the company’s stock worth $87,000 after buying an additional 799 shares in the last quarter. Principal Financial Group Inc. boosted its stake in Viridian Therapeutics by 9.7% during the 1st quarter. Principal Financial Group Inc. now owns 11,915 shares of the company’s stock valued at $209,000 after purchasing an additional 1,058 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in Viridian Therapeutics by 4.1% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 28,822 shares of the company’s stock valued at $505,000 after purchasing an additional 1,135 shares in the last quarter. Arizona State Retirement System raised its stake in shares of Viridian Therapeutics by 14.7% in the 2nd quarter. Arizona State Retirement System now owns 13,178 shares of the company’s stock worth $171,000 after buying an additional 1,688 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Viridian Therapeutics by 24.6% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,961 shares of the company’s stock valued at $156,000 after buying an additional 2,359 shares during the period.
Viridian Therapeutics Trading Down 1.3 %
VRDN opened at $23.05 on Monday. The firm has a market capitalization of $1.47 billion, a P/E ratio of -5.12 and a beta of 1.08. The firm’s 50 day moving average is $20.22 and its 200-day moving average is $16.11. The company has a quick ratio of 15.82, a current ratio of 15.82 and a debt-to-equity ratio of 0.05. Viridian Therapeutics has a 52-week low of $11.01 and a 52-week high of $25.39.
Viridian Therapeutics (NASDAQ:VRDN – Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($1.02) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.15). Viridian Therapeutics had a negative net margin of 79,185.77% and a negative return on equity of 83.18%. The firm had revenue of $0.07 million during the quarter, compared to analysts’ expectations of $0.09 million. Analysts expect that Viridian Therapeutics will post -3.94 EPS for the current fiscal year.
About Viridian Therapeutics
Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.
Featured Stories
- Five stocks we like better than Viridian Therapeutics
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- Do ETFs Pay Dividends? What You Need to Know
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- What is the Euro STOXX 50 Index?
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
Receive News & Ratings for Viridian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viridian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.